Open AccessThe protective effect of flagellin a and b as candidate vaccine against Pseudomonas aeruginosa respiratory infections
Author(s) -
Mohammed Jaafar Al-Anssari,
Alaa H. Al-Charrakh
Publication year - 2022
Publication title -
international journal of health sciences (ijhs) (en línea)
Language(s) - English
Resource type - Journals
eISSN - 2550-6978
pISSN - 2550-696X
DOI - 10.53730/ijhs.v6ns1.5497
Subject(s) - flagellin , pseudomonas aeruginosa , nasal administration , medicine , pneumonia , antibiotics , microbiology and biotechnology , cystic fibrosis , nostril , immunology , biology , bacteria , nose , surgery , receptor , genetics
Background: Multi drug resistance (MDR) P. aeruginosa consider the main cause of morbidity in hospitalize patients suffering from chronic airway infections such as chronic pulmonary disease, pneumonia and cystic fibrosis (CF). Also, the rapidly development of antibiotic resistance to the last generations of a broad spectrum antibiotic were detected for many P. aeruginosa isolates. Accordingly the vaccines have the potential to prevent and treatment such infections. Aim: The present study aimed to investigate active immunization strategies using flagellin in order to provide complete protection against MDR P. aeruginosa clinical isolates in the acute fatal respiratory infection in animal model. Methods: Flagellin a and flagellin b purified partially from P. aeruginosa as mentioned in previous study. After that the animals were immunized intranasally after sedative the animal by applying 10 μl of flagellin a (4.8 μg), or flagellin b (4.8 μgl) on each nostril for 100 mg weight of rat at weekly intervals. After week from the 6th dose, the animal were exposed to 2*107 CFU of P. aeruginosa intranasally directly into each nostril.